Comparative Pharmacology
Head-to-head clinical analysis: AQNEURSA versus POHERDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQNEURSA versus POHERDY.
AQNEURSA vs POHERDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQNEURSA is a monoclonal antibody that binds to and inhibits the activity of serum amyloid A (SAA), reducing amyloid deposition in tissues.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
AQNEURSA (ursodiol) is administered orally at 13–15 mg/kg/day in 2–4 divided doses for primary biliary cholangitis. For gallstone dissolution, the dose is 8–10 mg/kg/day in 2–3 divided doses, with a maximum of 300 mg twice daily.
POHERDY: No approved drug. No dosing available.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe cases).
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Approximately 70-80% of the dose is excreted renally as unchanged drug; 20-30% is eliminated via biliary/fecal routes.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid